AIRAscore

AIRAscore is a software medical device utilizing convolutional neural networks to automate the segmentation and volumetric quantification of brain structures, including white matter lesions, from MR images. It aims to provide clinicians with objective, standardized data by comparing patient-specific brain volumes and lesion characteristics against an age- and sex-adjusted reference collective, thereby supporting diagnostic workflows in neuroimaging.

AIRAscore is a software solution designed for the automated analysis of Magnetic Resonance (MR) brain images, offering rapid and reliable segmentation of key brain structures. It identifies and quantifies gray matter, white matter, cerebrospinal fluid, and, when present, white matter lesions, along with providing an additional classification of tissue anatomy. The system features two primary functions: "AIRAscore structure," which delivers volumetric measurements for segmented anatomical regions, including raw values, relative volumes to total intracranial capacity, and percentile comparisons against a reference population, and "AIRAscore MS," which further provides detailed information on the number, volume, and specific categorization (juxtacortical, periventricular, or infratentorial) of white matter lesions. The methodology involves processing DICOM-compliant T1-weighted (and optionally FLAIR) MR images from a single time point using specialized, static convolutional neural networks (CNNs) for segmentation. These results are then corrected for head size and statistically compared against an age- and sex-adjusted reference collective. AIRAscore, operating as a Software as a Service (SaaS) on internal servers, generates comprehensive DICOM reports detailing these volumetric findings and statistical classifications, as well as annotated DICOM images for visual inspection by expert clinicians, thereby aiming to automate and standardize the quantification process. Validation has reportedly confirmed its performance across diverse patient populations and scanner manufacturers.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the performance of AIRAscore's static neuronal networks compare to approaches using dynamically updated or continuously learning models, particularly in diverse patient populations or with evolving imaging protocols?; What is the statistical methodology and composition of the 'age- and sex-adjusted reference collective' used for percentile ranking, and how sensitive are the results to variations within this reference set?; Could the AIRAscore MS function be expanded to quantify other lesion characteristics beyond number, volume, and location (e.g., lesion activity, new vs. old lesions) if appropriate MR sequences were incorporated?; What specific performance metrics (e.g., Dice coefficient, Jaccard index, sensitivity, specificity) were achieved for the segmentation of different brain structures, especially for challenging cases like small or atypically located white matter lesions?; How does AIRAscore handle MR image artifacts or variations in image quality across different scanners and acquisition parameters, and what are the pre-processing steps involved before segmentation?